Table 2.
Drug-resistant profiles among newly diagnosed pulmonary TB patients with different BMI
| Drug resistance | Normal weight DR-TB cases (1210/6417, 18.86%) | Underweight DR-TB cases (387/2121, 18.25%) | Overweight DR-TB cases (76/373, 20.38%) | Obese DR-TB cases (11/46, 23.91%) | P value | ||
|---|---|---|---|---|---|---|---|
| Underweight group vs Normal weight group | Overweight group vs Normal weight group | Obese group vs Normal weight group | |||||
| DR-TB | 1210 (18.86%) | 387 (18.25%) | 76 (20.38%) | 11 (23.91%) | 0.532 | 0.467 | 0.383 |
| Any resistance to first-line drug | |||||||
| INH | 663 (10.33%) | 218 (10.28%) | 47 (12.6%) | 5 (10.87%) | 0.944 | 0.164 | 0.905 |
| RFP | 311 (4.85%) | 94 (4.43%) | 23 (6.17%) | 0 (0.00%) | 0.436 | 0.252 | 0.171 |
| EMB | 95 (1.48%) | 31 (1.46%) | 6 (1.61%) | 0 (0.00%) | 0.950 | 0.842 | 1.000 |
| SM | 863 (13.45%) | 246 (11.6%) | 60 (16.09%) | 9 (19.57%) | 0.028* | 0.149 | 0.226 |
| MR-TB (Total) | 718 (11.19%) | 249 (11.74%) | 36 (9.65%) | 8 (17.39%) | 0.488 | 0.358 | 0.184 |
| INH | 209 (3.26%) | 92 (4.34%) | 9 (2.41%) | 2 (4.35%) | 0.019* | 0.369 | 0.662 |
| RFP | 58 (0.9%) | 18 (0.85%) | 1 (0.27%) | 0 (0.00%) | 0.815 | 0.379 | 1.000 |
| EMB | 12 (0.19%) | 5 (0.24%) | 1 (0.27%) | 0 (0.00%) | 0.662 | 0.521 | 1.000 |
| SM | 436 (6.79%) | 130 (6.13%) | 25 (6.7%) | 6 (13.04%) | 0.286 | 0.945 | 0.094 |
| Others | 3 (0.05%) | 4 (0.19%) | 0 (0.00%) | 0 (0.00%) | 0.069 | 1.000 | 1.000 |
| MDR-TB (Total) | 219 (3.41%) | 65 (3.06%) | 20 (5.36%) | 0 (0.00%) | 0.438 | 0.047* | 0.407 |
| MDR1: INH + RFP | 48 (0.75%) | 15 (0.71%) | 4 (1.07%) | 0 (0.00%) | 0.849 | 0.531 | 1.000 |
| MDR2: INH + RFP + EMB + SM | 48 (0.75%) | 16 (0.75%) | 4 (1.07%) | 0 (0.00%) | 0.977 | 0.531 | 1.000 |
| MDR3: INH + RFP + SM | 108 (1.68%) | 30 (1.41%) | 12 (3.22%) | 0 (0.00%) | 0.395 | 0.029* | 1.000 |
| Others | 15 (0.23%) | 4 (0.19%) | 0 (0.00%) | 0 (0.00%) | 1.000 | 1.000 | 1.000 |
| PDR-TB | 270 (4.21%) | 72 (3.39%) | 20 (5.36%) | 3 (6.52%) | 0.098 | 0.284 | 0.444 |
| PDR1: INH + EMB | 6 (0.09%) | 2 (0.09%) | 1 (0.27%) | 0 (0%) | 1.000 | 0.327 | 1.000 |
| PDR2: INH + SM | 219 (3.41%) | 55 (2.59%) | 17 (4.56%) | 3 (6.52%) | 0.063 | 0.241 | 0.209 |
| PDR3: RFP + SM | 27 (0.42%) | 8 (0.38%) | 2 (0.54%) | 0 (0.00%) | 0.785 | 0.672 | 1.000 |
| PDR4: INH + EMB + SM | 10 (0.16%) | 3 (0.14%) | 0 (0.00%) | 0 (0.00%) | 1.000 | 1.000 | 1.000 |
| Others | 8 (0.12%) | 4 (0.19%) | 0 (0.00%) | 0 (0.00%) | 0.507 | 1.000 | 1.000 |
TB, tuberculosis; DR-TB, drug-resistant tuberculosis; MR-TB, mono-resistant tuberculosis; MDR-TB, multidrug resistant tuberculosis; PDR-TB, polydrug resistant tuberculosis; EMB, ethambutol; INH, isoniazid; RFP, rifampin; SM, streptomycin; BMI, body mass index;*P < 0.05
Underweight: BMI < 18.5 kg/m2; Normal weight: 18.5 kg/m2 ≥ BMI ≤ 24.9 kg/m2; Overweight: 25 kg/m2 ≥ BMI ≤ 29.9 kg/m2; Obese: BMI ≥ 30 kg/m2